Physician profile
Barry Paul
NPI 1760827539
$26,722.43
in general payments reported to CMS, 2019-2025
21 companies · $2,706 in 2025
The $2,706 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,021 · 2020: $5,753 · 2021: $3,405 · 2022: $499 · 2023: $1,272 · 2024: $6,067 · 2025: $2,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,890 · Food and Beverage: $1,555 · Honoraria: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,890.00 |
| Food and Beverage | $1,555.04 |
| Honoraria | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11,217.38 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $4,923.25 | 2021-2025 | Talvey, Darzalex, Tecvayli |
| Janssen Biotech, INC. | $3,674.22 | 2021-2025 | Talvey, Darzalex, Carvykti |
| Abbvie INC. | $2,200.00 | 2024 | |
| Genentech, INC. | $1,365.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,235.00 | 2021 | |
| Celltrion, INC. | $600.00 | 2025 | |
| Genzyme Corporation | $493.14 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $265.15 | 2022 | |
| Genentech USA, INC. | $143.30 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2023 | Calquence |
| Regeneron Healthcare Solutions, INC. | $113.67 | 2025 | Lynozyfic |
| Merck Sharp & Dohme LLC | $105.54 | 2019 | |
| Janssen Global Services, LLC | $85.84 | 2023 | Carvykti |
| Alnylam Pharmaceuticals INC. | $85.69 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $67.99 | 2023 | |
| Secura Bio, INC. | $12.26 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.